The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producing Th17 lymphocytes in patients with early rheumatoid arthritis

Rheumatology International

Volumn 35, Issue 1, 2015, Pages 171-175

  Guggino, G ^a   Giardina, A ^a   Ferrante, A ^a   Giardina, G ^a   Schinocca, C ^a   Sireci, G ^a   Dieli, F ^a   Ciccia, F ^a   Triolo, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

IL 17; Methotrexate; Rheumatoid arthritis; Steroid; Th17; Treg

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; METHYLPREDNISOLONE; TRANSCRIPTION FACTOR FOXP3; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TH17 CELL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERLEUKIN-10; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84928250699     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3030-2     Document Type: Article

References (13)

1. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238. doi:10.1038/nature04753
2. Wang W, Shao S, Jiao Z, Guo M, Xu H, Wang S (2012) The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 32(4):887–893. doi:10.1007/s00296-010-1710-0
3. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA et al (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200(3):277–285. doi:10.1084/jem.20040165
4. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M et al (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32
5. Afzali B, Mitchell PJ, Edozie FC, Povoleri GA, Dowson SE, Demandt L et al (2013) CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur J Immunol 43(8):2043–2054. doi:10.1002/eji.201243296
6. Scottà C, Esposito M, Fazekasova H, Fanelli G, Edozie FC, Ali N et al (2013) Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica 98(8):1291–1299. doi:10.3324/haematol.2012.074088
7. Ciccia F, Alessandro R, Rodolico V, Guggino G, Raimondo S, Guarnotta C et al (2013) IL-34 is overexpressed in the inflamed salivary glands of patients with Sjogren’s syndrome and is associated with the local expansion of pro-inflammatory CD14(bright)CD16+ monocytes. Rheumatology 52(6):1009–1017. doi:10.1093/rheumatology/kes435
8. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S (2009) Type 17 T helper cells—origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 6:325–331. doi:10.1038/nrrheum.2009.80
9. Miossec P (2003) Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 48(3):594–601. doi:10.1002/art.10816
10. Furst DE, Emery P (2014) Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology. doi:10.1093/rheumatology/ket414
11. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J et al (2012) Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 64(8):2499–2503. doi:10.1002/art.34477
12. Brunsing RL, Prossnitz ER (2011) Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1. Immunology 134(1):93–106. doi:10.1111/j.1365-2567.2011.03471.x
13. Szalay B, Vásárhelyi B, Cseh A, Tulassay T, Deák M, Kovács L et al (2013) The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study. Clin Rheumatol. doi:10.1007/s10067-013-2352-x